Skip to search formSkip to main contentSkip to account menu

MAGE-3.A1 Peptide Vaccine

Known as: HLA-A1-Restricted MAGE-3 Peptide Vaccine, MAGE-3.A1 
A synthetic peptide cancer vaccine consisting of human leukocyte antigen HLA-A1-restricted peptide derived from human melanoma antigen 3 (MAGE-3… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
We previously characterized the CTL response of a melanoma patient who experienced tumor regression following vaccination with an… 
Highly Cited
2008
Highly Cited
2008
Tumor regressions have been observed in a small proportion of melanoma patients vaccinated with a MAGE-A3 peptide presented by… 
Highly Cited
2005
Highly Cited
2005
Melanoma patients have high frequencies of T cells directed against antigens of their tumor. The frequency of these antitumor T… 
2005
2005
We describe an HLA-A1 melanoma patient who has mounted a spontaneous cytolytic T cell (CTL) response against an antigenic peptide… 
Highly Cited
2004
Highly Cited
2004
The cancer-germline gene MAGE-3 codes for tumor-specific antigens recognized on many tumors by T lymphocytes. A MAGE-3 antigen… 
Highly Cited
2003
Highly Cited
2003
Vaccination with mature, monocyte-derived dendritic cells (DC) pulsed with the MAGE-3168–176 peptide, which is presented by HLA… 
Highly Cited
2003
Highly Cited
2003
We have analyzed the T cell responses of HLA-A1 metastatic melanoma patients with detectable disease, following vaccination with… 
Highly Cited
2001
Highly Cited
2001
Cell surface expression of HLA class I/peptide complexes on tumor cells is a key step in the generation of T‐cell‐based immune… 
2001
2001
Cell surface expression of HLA class I/peptide complexes on tumor cells is a key step in the generation of T-cell-based immune… 
Highly Cited
1999
Highly Cited
1999
Thirty‐nine tumor‐bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE‐3.A1 peptide…